musketeer
bayer ag - Ελαιώδες εναιώρημα (od) - Δραστική ουσία: diflufenican 15% β/ο, iodosulfuron-methyl-sodium 1% β/ο, Αντιφυτοτοξικός παράγοντας: mefenpyr-diethyl 5 % β/ο Βοηθητικές ουσίες: 83,76 % β/β
vinblastina/ciclum farma pd.sol.inf 10mg/vial
ΙΦΕΤ ΑΕ 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51 153 51, Παλλήνη Αττικής 210.6603400-6603522 - vinblastine sulfate - pd.sol.inf (ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 10mg/vial - vinblastine sulfate
vioxxacute 25mg/tab tab
vianex a.e. - rofecoxib - ΔΙΣΚΙΟ - 25mg/tab
vioxxacute 50mg/tab tab
vianex a.e. - rofecoxib - ΔΙΣΚΙΟ - 50mg/tab
vidaza
bristol-myers squibb pharma eeig - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine mylan
mylan ireland limited - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
pulvo-hexa 200.000iu/g+1%(w/w) aer.top
fournier-gerolymatos a.e. - other cicatrizants - ΑΕΡΟΛΥΜΑ ΓΙΑ ΤΟΠΙΚΗ ΧΡΗΣΗ - 200.000iu/g+1%(w/w) - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ - other cicatrizants
madecassol 10mg/tab tab
Α. ΝΙΚΟΛΑΚΟΠΟΥΛΟΣ Α.Ε. - other cicatrizants - ΔΙΣΚΙΟ - 10mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ - other cicatrizants
ilon ointment
ΦΑΡΑΝ ΑΒΕΕ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ - other cicatrizants - ΑΛΟΙΦΗ - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ - other cicatrizants